Crescendo Biologics raises a $70,000,000 series B round from Andera Partners and Quan Capital.
April 30, 2018
Crescendo Biologics raises a $70,000,000 series B round.
Crescendo Biologics raises a $19,500,000 series A round from EMBL Ventures.
January 20, 2010
Crescendo Biologics raises a $7,300,000 series A round from Avlar BioVentures.
Documentaries, videos and podcasts
May 20, 2021
First clinical trial from Crescendo's proprietary pipeline of novel, targeted T cell enhancing Humabody® therapeutics; initial clinical data expected in 2022
May 10, 2021
Crescendo Biologics Ltd, a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, announces the appointment of Dr Michael Booth as Chief Financial Officer.